Bevixa 100

Bevacizumab is an anticancer medication. It is used in the treatment of cancer of colon and rectum, non-small cell lung cancer, kidney cancer, brain tumor, ovarian and cervical cancer. It helps to prevent the growth of new blood vessels that feed tumors and stops tumors from growing. Bevacizumab is an effective medicine, first-line option when used together with other cancer medicines. It is given as an infusion. That means you get it through a small needle in your vein or through a port, which is a device placed under your skin. The doctor will decide your dose and duration and will check you for signs of an infusion reaction such as high blood pressure and trouble breathing. You keep taking Bevacizumab as long as your disease is controlled and your side effects are manageable. Your doctor will determine whether you should stop taking it or not. You may be advised to check blood pressure and levels of protein in urine while you are taking this medication. The most common side effects of this medicine include rectal bleeding, taste change, and headache. Inform your doctor that you are taking this medication before undergoing any surgical procedure, as the drug has ability to lower the ability of wound healing. Other than this, it also enhances your risk of bleeding thus if you notice any unusual bleeding or bleeding consult with your doctor immediately. Inform your doctor if you are pregnant, planning pregnancy or breastfeeding. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. Bevacizumab is a anti-angiogenic medication. It works by blocking a protein called vascular endothelial growth factor (VEGF). This stops the formation of blood vessels that bring oxygen and nutrients to cancerous cells.

• Cancer of colon and rectum • Non-small cell lung cancer • Kidney cancer • Brain tumor • Ovarian cancer • Cervical cancer

Bevacizumab binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF reduces the vascularisation of tumours, normalises remaining tumour vasculature and inhibits the formation of new tumour vasculature thereby inhibiting tumour growth.

Adult Dose: General: Bevacizumab should be prepared by a healthcare professional using aseptic technique. The initial Bevacizumab dose should be delivered over 90 min as an IV infusion. If the 1st infusion is well tolerated, the 2nd infusion may be administered over 60 min. If the 60-min infusion is well tolerated, all subsequent infusions may be administered over 30 min. Dose reduction of Bevacizumab for adverse events is not recommended. If indicated, Bevacizumab should either be permanently discontinued or temporarily suspended. Metastatic Colorectal Cancer (mCRC): The recommended dose of Bevacizumab, administered as an IV infusion, is as follows: First-line Treatment: 5 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg of body weight given once every 3 weeks. Second-line Treatment: 10 mg/kg of body weight given every 2 weeks or 15 mg/kg of body weight given once every 3 weeks. It is recommended that Bevacizumab treatment be continued until progression of the underlying disease. Locally Recurrent or Metastatic Breast Cancer (mBC): The recommended dose of Bevacizumab is 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of body weight given once every 3 weeks as an IV infusion. Clinical benefit in mBC patients has also been demonstrated at a dose of 7.5 mg/kg of body weight given once every 3 weeks as an IV infusion. It is recommended that Bevacizumab treatment be continued until progression of the underlying disease. Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC): Bevacizumab is administered in addition to platinum-based chemotherapy for up to 6 cycles of treatment followed by Bevacizumab as a single agent until disease progression. The recommended dose when used in addition to cisplatin-based chemotherapy is 7.5 mg/kg of body weight given once every 3 weeks as an IV infusion. The recommended dose when used in addition to carboplatin-based chemotherapy is 15 mg/kg of body weight given once every 3 weeks as an IV infusion. Advanced and/or Metastatic Renal Cell Cancer (mRCC): The recommended dose is 10 mg/kg of body weight given once every 2 weeks as an IV infusion. It is recommended that treatment be continued until progression of the underlying disease. Malignant Glioma (WHO Grade IV)-Glioblastoma: The recommended dose of Bevacizumab is 10 mg/kg of body weight given once every 2 weeks or 15 mg/kg of body weight given once every 3 weeks as an IV infusion. Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer: The recommended dose is 15 mg/kg of body weight given once every 3 weeks. Exudative age-related macular degeneration 1.25 mg (in 0.05mL of solution) administered by intravitreal injection once monthly

Your doctor or nurse will give you this medicine. Kindly do not self administer.

If you miss a dose of Bevacizumab, please consult your doctor.

Common: • Rectal bleeding • Taste change • Headache • Nosebleeds • Back pain • Dry skin • High blood pressure • Protein in urine • Inflammation of the nose

[UNSAFE] Bevacizumab may cause side effects which could affect your ability to drive. Sleepiness and fainting have been reported with Bevacizumab and this may impair your ability to drive. Bevacizumab is an effective, first-line option when used together with other medicines for certain types of cancers such as colorectal, lung, cervical, and kidney cancers. Bevacizumab is given as an infusion. Your doctor or nurse will monitor you for signs of an infusion reaction such as high blood pressure and trouble breathing. It can lower your wound healing ability. Inform your doctor that you are taking this medication before undergoing any surgical procedure. It can increase the risk of bleeding. Inform your doctor if you notice any unusual bleeding or bleeding that doesn't stop easily. Your doctor may regularly check your blood pressure and levels of protein in your urine while you are on Bevacizumab.

Hypersensitivity to any component Recent hemoptysis

Irinotecan/5–fluorouracil/leucovorin The incidence of epistaxis and grade 1 or 2 hemorrhage (including GI hemorrhage, minor gum bleeding, vaginal hemorrhage) was greater in patients receiving bevacizumab plus irinotecan/5-fluorouracil/leucovorin compared with patients receiving irinotecan/5-fluorouracil/leucovorin plus placebo. Closely monitor the patient during coadministration. Live vaccines The administration of live vaccines to patients receiving bevacizumab may result in a reduced immune response. Avoid coadministration. Paclitaxel Decreased paclitaxel exposure was seen when paclitaxel/carboplatin was given in combination with bevacizumab. Closely monitor the patient during coadministration. Sunitinib Coadministration of bevacizumab and sunitinib has been reported to cause unexpected severe toxicity (eg, microangiopathic hemolytic anemia). Coadministration of sunitinib and bevacizumab is not recommended.

[CONSULT YOUR DOCTOR] It is not known whether it is safe to consume alcohol with Bevacizumab. Please consult your doctor.

[CONSULT YOUR DOCTOR] Bevacizumab may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

[CONSULT YOUR DOCTOR] Bevacizumab is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

[SAFE IF PRESCRIBED] Bevacizumab is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Bevacizumab may not be needed in these patients. Please consult your doctor. [SAFE IF PRESCRIBED] Bevacizumab is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Bevacizumab may not be needed in these patients. Please consult your doctor.

What is the purpose of Chemotherepy given at the time of radiotherapy in ca lung small cell carcinoma This is given to enhance the therapeutic effect of radiation therapy which is curative for small cell lung cancer. I want to know the symptoms of cancer as I am a smoker Symptoms for cancer depends upon which organ involved. For smokers , definitely chronic , they have possibility to develop lung cancer, head and neck cancers, oesophagus cancer, pancreatic cancer, stomach cancer and so more on. General symptoms would be like loss of appetite, weight loss, low grade fever in some cases, chronic cough for long time. Sir my brother have skin cancer can you do something for save his life ?? Treatment of cancer depends on whether it is localized or metastatic cancer My mother have ovarian cancer. I want to consult docter how much serious my mother according to reports When will i get my answer U have to do FNAC from tumorIf positive for cancer Chemotherapy will be done If any symtom of brest cancer if have whats the cure First is confirmation of breast cancerChance of cure depends on stage of cancer Smears show metastatic mucinous adenocarcinoma.HISTOPATHOLOGY REPORT.sir is there any treatment Sir my mom firstly suffered from stomach pain.Then say about doing ultra sound test which is as:Neoplasm Stomach Pylrus.Fresh blood in corpus .polypoid growth in pylrus biopy taken from HPE Sir please help doctors already said there is no treatment for this stomach cancer disease Cancer is treated based on stage of cancerPlease upload reports of Ultrasound and endoscopy I seem to have lung cancer , becoz all the symptoms are same as lung cancer. I test my blood, they suggests me that it is highly probable to lung cancer. Sir what can i do now. This is in preliminary stage Do you think that lung cancer is diagnosed from blood